Portage Biotech Inc. (PRTG) announced the outcome from the company's review of its pipeline in the context of the current capital raising market conditions. The company is implementing a cost-savings plan that includes a reduction in internal and contracted workforce, with remaining employees focusing primarily on pursuing the adenosine clinical programs.

Portage Biotech Inc.（PRTG）宣布了该公司在当前融资市场条件下对其管道进行审查的结果。该公司正在实施一项成本节约计划，其中包括减少内部和合同员工，其余员工主要专注于腺苷临床项目。

After a review of funding requirements, the Board has made the decision to pause further drug development in the PORT-2 iNKT program.Ian Walters, CEO, said: 'The company will evaluate a range of potential strategic options which may include among other things, finding a partner for our iNKT program or other corporate transactions.' Shares of Portage Biotech are up 16% in pre-market trade on Thursday..

在审查了资金需求后，董事会决定暂停PORT-2 iNKT计划中的进一步药物开发。首席执行官伊恩·沃尔特斯（IanWalters）表示：“公司将评估一系列潜在的战略选择，其中可能包括为我们的iNKT计划或其他公司交易寻找合作伙伴。”周四上市前交易中，Portage Biotech的股价上涨了16%。。

For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News

有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局（FDA）决定生物技术股